Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil

Clinical and Investigative Medicine

Volumn 32, Issue 3, 2009, Pages

  Cinemre, Hakan ^a   Bilir, Cemil ^a   Gokosmanoglu, Feyzi ^a   Akdemir, Nermin ^b   Erdogmus, Besir ^a   Buyukkaya, Ramazan ^a  

^a DUZCE UNIVERSITY   (Turkey)

^b Kecioren Teaching and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; PROPYLTHIOURACIL; THYROTROPIN; THYROXINE;

ADULT; ARTERY BLOOD FLOW; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; DOPPLER FLOWMETRY; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GENDER; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MALE; PRIORITY JOURNAL; REMISSION; SMOKING; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTITHYROID AGENTS; FEMALE; GRAVES DISEASE; HUMANS; MALE; PROPYLTHIOURACIL; SEX FACTORS; SMOKING; THYROXINE; TREATMENT FAILURE;

EID: 67649362214     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Iagaru A, McDougall IR. Treatment of thyrotoxicosis J Nucl Med 2007;48:379-389
2. Stålberg P, Svensson A, Hessman O, Akerström G, Hellman P. Surgical treatment of Graves' disease: evidence-based approach. World J Surg 2008;32:1269-1277
3. Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008;358:2594-2605
4. Baskin HJ, Cobin RH, Duick DS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457-469 (Pubitemid 35423133)
5. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ 2006;332:1369-1373 (Pubitemid 44365354)
6. Wartofsky L. Has the use of antithyroid drugs for Graves' disease become obsolete? Thyroid 1993;3:335-344
7. Cooper DS. Clinical practice. Graves' disease. N Engl J Med 2005;352:905-917
8. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678-3682 (Pubitemid 30828574)
9. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241-1245 (Pubitemid 17074785)
10. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038-1042 (Pubitemid 32269346)
11. Huang SM, Chow NH, Lee HL, Wu TJ. The value of color flow Doppler ultrasonography of the superior thyroid artery in the surgical management of Graves disease. Arch Surg 2003;138:146-151 (Pubitemid 36216278)
12. Iitaka M, Miura S, Yamanaka K, et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1998;83:3908-3912 (Pubitemid 28513571)
13. Figueroa-Vega N, Sanz-Cameno P, Moreno-Otero R, Sánchez-Madrid F, González-Amaro R, Marazuela M. Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J Clin Endocrinol Metab 2009 Jan 13 [Epub ahead of print].
14. Bogazzi F, Bartalena L, Brogioni S, et al. Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. Eur J Endocrinol 1999;140:452-456
15. Saleh A, Cohnen M, Fürst G, Mödder U, Feldkamp J. Prediction of relapse after antithyroid drug therapy of Graves' disease: value of color Doppler sonography. Exp Clin Endocrinol Diabetes 2004;112:510-513 (Pubitemid 39457628)
16. Ueda M, Inaba M, Kumeda Y, et al. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves' disease relapse. Clin Endocrinol (Oxf) 2005;63:657-662 (Pubitemid 41779639)
17. Cappelli C, Gandossi E, Castellano M, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocr J 2007;54:713-720
18. Miao J, Zhao YJ, Wang S, et al. Prognostic factors in the relapse of Graves disease. Zhonghua Nei Ke Za Zhi 2008;47:185-188